Insulin Pricing
This MDL consolidates claims alleging that major insulin manufacturers and pharmacy benefit managers engaged in a scheme to artificially inflate the published list prices of insulin products: manufacturers allegedly paid substantial rebates to PBMs to secure preferential formulary placement, then raised list prices to cover those payments, rendering the published prices fraudulent relative to legitimate market pricing. Centralized in the District of New Jersey in 2023, the docket carries 516 pending actions, brought largely by third-party payors, benefit plans, and other institutional purchasers, with claims spanning wire and mail fraud, RICO violations, and state consumer-protection theories.
What drives resolution risk and duration in this docket is the layered complexity of proving a rebate-and-list-price scheme across multiple manufacturer and PBM defendants, each with its own contracting and rebate structure, combined with the heightened pleading and proof standards that come with civil RICO claims. That combination, an economically complex pricing-conspiracy theory paired with a demanding fraud-based legal framework, distinguishes this docket from a more conventional purchaser-overcharge antitrust matter and likely extends the timeline for resolving threshold liability questions before the actions can move toward class-wide or aggregated resolution.
For anyone tracking how pharmaceutical-pricing litigation is evolving beyond conventional antitrust theories, this docket is a significant current example of drug-pricing claims framed through a RICO and consumer-fraud lens rather than solely an antitrust one, reflecting a broader pattern in pharmaceutical benefit-manager litigation. Criterica Intelligence's platform tracks this doctrinal shift, and the added proof complexity it brings, across pharmaceutical-pricing MDLs generally.
That major insulin manufacturers paid substantial rebates to pharmacy benefit managers for preferential formulary placement and then raised published list prices to cover those payments, rendering the list prices disconnected from legitimate market pricing.
Plaintiffs allege the rebate-and-list-price scheme amounts to wire and mail fraud actionable under civil RICO, in addition to more conventional state consumer-protection theories, reflecting an evolving approach to drug-pricing litigation.
Proving a coordinated rebate-and-pricing scheme across multiple manufacturer and PBM defendants, each with distinct contracting structures, combined with RICO's heightened proof standards, adds layers of complexity beyond a conventional antitrust overcharge theory.
A shift toward framing drug-pricing disputes through RICO and consumer-fraud theories rather than antitrust law alone, a doctrinal trend Criterica Intelligence tracks across pharmaceutical-pricing MDLs generally.
Statistics shown reflect historical or illustrative model outputs derived from real case data. They are not predictions or guarantees of any individual outcome. Litigation results depend on facts, jurisdiction, judge, and counsel, and vary case by case. Model accuracy is subject to selection effects and changing legal dynamics.